Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2017-12-22 AGM Information
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Bulletin from the extraordinary general meeting of Hansa Medical AB (publ)
AGM Information Classification · 99% confidence The document is a press release dated December 22, 2017, detailing resolutions passed at an extraordinary general meeting (EGM). The primary resolution discussed is the approval of the board's decision to issue new ordinary shares via a directed issue to institutional investors to secure capital. This action directly relates to changes in the company's capital structure and fundraising activities. While it occurred at a general meeting, the core subject is the share issuance/financing, making 'Capital/Financing Update' (CAP) the most appropriate classification over AGM-R (which is for presentations/materials) or DVA (which is for voting results). Since it is a formal announcement of a capital action, CAP is preferred over the general 'RNS' fallback.
2017-12-22 English
Kommuniké från extra bolagsstämma i Hansa MedicalAB (publ)
AGM Information Classification · 99% confidence The document is a press release dated December 22, 2017, detailing decisions made at an Extraordinary General Meeting (EGM) of Hansa Medical AB. The key decision mentioned is the approval of a directed new share issue (nyemission) to institutional investors. This action directly relates to changes in the company's capital structure and fundraising activities. Based on the definitions, 'Capital/Financing Update' (CAP) is the most appropriate classification for announcements regarding fundraising, financing activities, or capital structure changes, which this document explicitly covers through the approval of a share issue.
2017-12-22 Swedish
Kallelse till extra bolagsstämma i Hansa Medical AB (publ)
AGM Information Classification · 98% confidence The document is titled "Kallelse till extra bolagsstämma i Hansa Medical AB (publ)" which translates to 'Notice of Extraordinary General Meeting in Hansa Medical AB (publ)'. It details the date, time, location, registration procedures, agenda items (including a proposal for a directed new share issue), and voting requirements for an upcoming shareholder meeting. This content directly corresponds to the purpose of a notice for a general meeting, which is often related to proxy solicitation or the meeting itself. Since it is a formal notice calling shareholders to vote on specific matters, it aligns best with the category for materials related to shareholder meetings and voting information. The closest specific category is 'AGM Information' (AGM-R), although this is an 'Extraordinary' meeting, the function is the same. Alternatively, it could be considered a Proxy Solicitation document (PSI) as it solicits participation and provides necessary information for voting. Given the explicit call to an 'extra bolagsstämma' (Extraordinary General Meeting) and the detailed agenda, AGM-R is the most appropriate fit for the meeting notice itself, as PSI often refers to the formal proxy statement materials sent out prior to the meeting.
2017-11-30 Swedish
Notice of Extraordinary General Meeting of Hansa Medical AB (publ)
AGM Information Classification · 99% confidence The document is explicitly titled 'Notice of Extraordinary General Meeting of Hansa Medical AB (publ)' and details the date, time, location, registration procedures, proxy rules, and the proposed agenda items for this meeting. The agenda includes a proposal regarding the approval of a board resolution on issuing new ordinary shares. This content directly relates to the formal process and materials surrounding a shareholder meeting, specifically an Extraordinary General Meeting (EGM). The closest matching category is 'AGM Information' (AGM-R), which covers presentations and materials shared during the Annual General Meeting, and by extension, other general shareholder meetings like EGMs, especially when they involve voting on key corporate actions like share issuance. It is not a DEF 14A (Remuneration), DVA (Voting Results), or PSI (Proxy Solicitation), as it is the *notice* calling the meeting, not the final results or the full proxy statement soliciting votes, although it contains elements of both. Given the focus on convening the meeting and outlining proposals, AGM-R is the most appropriate fit for general meeting documentation.
2017-11-30 English
Hansa Medicals styrelse har beslutat att genomföra en riktad nyemission om 545 MSEK
Capital/Financing Update Classification · 98% confidence The document text is a press release announcing that the Board of Directors of Hansa Medical AB has decided to conduct a directed new share issue (nyemission) to raise 545 MSEK from institutional investors, subject to approval at an Extraordinary General Meeting (EGM). This action directly relates to fundraising, capital structure changes, and securing financing for future development. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). Since it is the primary announcement detailing the financing event, it is classified as CAP rather than a general Regulatory Filing (RNS).
2017-11-29 Swedish
Hansa Medical’s Board of Directors has resolved on a directed share issue of SEK 545 million
Share Issue/Capital Change Classification · 98% confidence The document explicitly details a resolution by the Board of Directors to conduct a 'directed share issue of SEK 545 million' subject to shareholder approval at an Extraordinary General Meeting (EGM). This action involves issuing new shares to raise capital and discusses the resulting dilution and use of proceeds. This directly corresponds to the definition of Capital/Financing Update (CAP), which covers company fundraising and capital structure changes. It is not an Annual Report (10-K), an Earnings Release (ER), or a simple Dividend Notice (DIV).
2017-11-29 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.